Table 5 Comparison of clinical characteristics in NSCLC patients with fibrosing ILD according to KL-6
Characteristic | KL-6 ≥ 1,000 (n = 29) | KL-6 < 1,000 (n = 69) | P Value |
|---|---|---|---|
Type of ILD | Â | Â | 0.807 |
 IPF | 18 (62.1) | 41 (59.4) |  |
 Non-IPF ILD | 11 (37.9) | 28 (40.6) |  |
Age, years | 67.5 ± 7.1 | 71.1 ± 6.9 | 0.030 |
Male | 27 (93.1) | 64 (92.8) | 0.951 |
BMI, kg/m2 | 24.0 ± 3.58 | 24.7 ± 3.2 | 0.899 |
Ever-smoker | 27 (93.1) | 64 (92.8) | 0.516 |
Pulmonary function test | Â | Â | Â |
 FVC (predicted). % (n = 97) | 68.3 ± 17.3 | 79.0 ± 16.0 | 0.007 |
 FEV1 (predicted), % (n = 97) | 72.9 ± 15.6 | 83.4 ± 15.5 | 0.004 |
 TLC (predicted), % (n = 56) | 72.5 ± 13.9 | 83.6 ± 11.2 | 0.003 |
 DLco (predicted), % (n = 56) | 46.1 ± 16.5 | 58.7 ± 16.0 | 0.001 |
Type of NSCLC | Â | Â | 0.668 |
 Adenocarcinoma | 17 (58.6) | 34 (49.3) |  |
 Squamous cell carcinoma | 11 (37.9) | 34 (49.3) |  |
 Others | 1 (3.5) | 1 (1.4) |  |
Stage of NSCLC | Â | Â | 0.120 |
 I | 5 (17.2) | 28 (40.6) |  |
 II | 7 (24.1) | 9 (13.0) |  |
 III | 7 (24.1) | 16 (23.2) |  |
 IV | 10 (34.5) | 16 (23.2) |  |
Initial treatment for NSCLC | Â | Â | Â |
 Surgery | 6 (20.7) | 26 (37.7) | 0.102 |
 Chemotherapy | 9 (31.0) | 14 (20.3) | 0.252 |
 Radiotherapy | 5 (17.2) | 17 (24.6) | 0.423 |
 CCRT | 1 (3.4) | 3 (4.3) | 0.837 |
 Best supportive care | 8 (27.6) | 9 (13.0) | 0.083 |
ILD treatment | Â | Â | Â |
 Antifibrotics | 16 (55.2) | 40 (58.0) | 0.798 |
 Corticosteroid ± IS | 20 (69.0)a | 25 (36.2)b | 0.003 |
  Initial treatment | 8 (27.6) | 7 (10.1) | 0.029 |
  Acute exacerbation | 15 (51.7) | 16 (23.2) | 0.006 |
  RT pneumonitis | 0 (0.0) | 3 (4.3) | 0.254 |
Acute exacerbation | 15 (51.7) | 14 (20.3) | 0.002 |
Overall mortality | 19 (65.5) | 22 (31.9) | 0.002 |
 AE-related death | 11 (57.9) | 6 (27.3) | 0.047 |
 Infection-related death | 2 (10.5) | 6 (27.3) | 0.249 |
 Unknown | 6 (31.6) | 10 (45.5) | 0.364 |